This prospective pilot study evaluated the safety and efficacy of intracavernosal injections of placental matrix-derived mesenchymal stem cells (PM-MSCs) in five male patients aged 45–59 with Peyronie’s disease (PD). Patients received a single PM-MSC injection and were followed at 6 weeks, 3 months, and 6 months. Significant improvements were observed
This 2010 pilot study assessed the safety and efficacy of intracavernosal injections of human umbilical cord blood stem cells (hUCBSCs) in seven male patients (ages 57–87) with type 2 diabetes mellitus and refractory erectile dysfunction (ED). Each patient received a single injection of 1.5×10⁷ hUCBSCs without immunosuppression. Over a 9-month
This 2021 systematic review evaluated clinical studies on stem cell therapy (SCT) for erectile dysfunction (ED), highlighting its potential as a regenerative treatment. Various stem cell types—adipose-derived (ADSC), bone marrow-derived (BMSC), umbilical cord, and placental—have been administered primarily via intracavernosal injection. Clinical trials reported improvements in erectile function, with some
This 2022 case series evaluated the safety and efficacy of intracavernosal injection (ICI) of incobotulinumtoxinA (Xeomin®) 100 U as an adjunct to standard pharmacological treatments (PDE5 inhibitors or PGE1 ICIs) in 66 men with difficult-to-treat erectile dysfunction (ED). Approximately 52% of patients achieved a clinically meaningful improvement in International Index
This 2021 randomized, single-blind clinical trial evaluated the safety and efficacy of intracavernosal injection of autologous oral mucosa-derived mesenchymal stem cells (MSCs) in 20 diabetic men with erectile dysfunction (ED) unresponsive to standard treatments. Participants were divided into intervention (n=10) and control (n=10) groups. The intervention group received a single
This 2023 review outlines current and emerging treatments for erectile dysfunction (ED), affecting approximately 40% of men aged 40–70. First-line therapies include oral phosphodiesterase type 5 inhibitors (PDE5i) such as sildenafil and tadalafil, and intracavernosal injections of agents like prostaglandin E1. Experimental pharmacotherapies under investigation include dopamine D₄ receptor agonists,
This systematic review and meta-analysis evaluated the efficacy and safety of intracavernosal platelet-rich plasma (PRP) injections for treating mild to moderate erectile dysfunction (ED), analyzing three randomized controlled trials with 221 patients. The PRP group showed significant improvements in erectile function based on the International Index of Erectile Function-Erectile Function
